Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 235Lung Neoplasms 106Ovarian Neoplasms 81Breast Neoplasms 81Fallopian Tube Neoplasms 51Small Cell Lung Carcinoma 42Neoplasms 41Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 25Adenocarcinoma of Lung 25Parkinson Disease 4, Autosomal Dominant Lewy Body 24Carcinoma 23Neoplasm Metastasis 20Carcinoma, Ovarian Epithelial 18Melanoma 14Lymphoma, Large B-Cell, Diffuse 14Carcinoma, Squamous Cell 14Brain Neoplasms 14Prostatic Neoplasms 13Recurrence 12Lymphoma 12Endometrial Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Esophageal Neoplasms 11Lymphoma, Non-Hodgkin 10Hodgkin Disease 10Brenner Tumor 10Urinary Bladder Neoplasms 9Central Nervous System Neoplasms 9

Interventions

Bevacizumab 3Temozolomide 2Sorafenib 2pembrolizumab 1Valproic Acid 1Therapeutics 1Sildenafil Citrate 1Radiosurgery 1Irinotecan 1Equipment and Supplies 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurologic Manifestations × Carboplatin × Clear all
NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
35 enrolled 17 charts
CNS

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡